ArticleNature2026
Inhibitors supercharge kinase turnover through native proteolytic circuits.
Abstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Modulating pseudokinase conformation from the ATP-binding site.Structure (London, England : 1993) · 2026Article
- Post-translational modifications in metabolic reprogramming: implications for metabolic therapy and immunotherapy in cancer.Signal transduction and targeted therapy · 2026Review
- Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies.Nature reviews. Drug discovery · 2026Review
- On the Scope of DCAF1-Recruiting PROTACs Degrading Protein Kinases.Journal of medicinal chemistry · 2026Article
- Targeted protein degradation: bridging chemical biology and clinical translation.Acta pharmacologica Sinica · 2026Review
- Low-dose EGFR inhibition unlocks ferroptosis susceptibility to sensitize chemotherapy in EGFR-high triple-negative breast cancer.The Journal of biological chemistry · 2026Article
- A RIPK2 activity signature in prostate cancer: Modulation by RIPK2 inhibition and clinical association.Translational oncology · 2026Article
- In vitro and in silico modelling of ROS1-positive non-small cell lung cancer reveals fusion-dependent tyrosine kinase inhibitor responses.Molecular oncology · 2026Article
- Covalent Reprogramming of Kinase Binders to Modulate Protein Abundance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Small-molecule modulators of HIPK4 activity and proteostasis.bioRxiv : the preprint server for biology · 2026Article
- MELK inhibition disrupts actin cytoskeleton and broadly restricts human coronavirus infections.Nature communications · 2026Article
- Restoring the 14-3-3/CRAF regulatory interaction in Noonan syndrome using molecular glues.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Monovalent pseudo-natural products supercharge degradation of IDO1 by its native E3 KLHDC3.Nature chemistry · 2026Article
- From Serendipity to Strategy: Rationalizing Molecular Glue Discovery and Proximity-Induced Pharmacology through Chemical Biology.Journal of the American Chemical Society · 2026Review
- Expanding the toolbox to develop IAP-based degraders of TEAD transcription factors.Communications chemistry · 2026Article
- Covalent Reprogramming of Kinase Binders to Modulate Protein Homeostasis.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Natalie S ScholesCeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0002-1053-4079
Martino BertoniInstitute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.
Arnau Comajuncosa-CreusInstitute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.ORCID 0000-0002-9633-7665
Katharina KladnikCeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Xuefei GuoBeijing Frontier Research Center for Biological Structure, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.ORCID 0000-0001-7135-0954
Fabian FrommeltCeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0003-3666-8005
Matthias HinterndorferCeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0003-2435-4690
Hlib RazumkovDepartment of Chemistry, Stanford School of Humanities and Sciences, Stanford University, Stanford, CA, USA.ORCID 0000-0001-6150-8172
Polina ProkofevaChair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany.
Martin P SchwalmInstitute of Pharmaceutical Chemistry, Goethe University, Frankfurt am Main, Germany.ORCID 0000-0002-1252-1829
Florian BornInstitute of Pharmaceutical Chemistry, Goethe University, Frankfurt am Main, Germany.
Sandra RoehmInstitute of Pharmaceutical Chemistry, Goethe University, Frankfurt am Main, Germany.ORCID 0000-0003-3999-712X
Hana ImrichovaCeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0003-0385-1823
Brianda L SantiniCeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Eleonora BaroneCeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0002-4788-7070
Caroline SchätzCeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Miquel Muñoz I OrdoñoCeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0009-0003-4391-6393
Severin LechnerCeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Andrea RukavinaCeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0001-8254-9360
Iciar SerranoCeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Miriam AbeleCeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0003-0084-2999
Anna KorenCeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0003-2528-4970
Stefan KubicekCeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0003-0855-8343
Stefan KnappInstitute of Pharmaceutical Chemistry, Goethe University, Frankfurt am Main, Germany.ORCID 0000-0001-5995-6494
Nathanael S GrayDepartment of Chemical and Systems Biology, ChEM-H, Stanford School of Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0001-5354-7403
Giulio Superti-FurgaCeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0002-0570-1768
Bernhard KusterChair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany.ORCID 0000-0002-9094-1677
Yigong ShiSchool of Life Sciences, Westlake University, Hangzhou, China.ORCID 0000-0003-2030-168X
Patrick AloyInstitute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.ORCID 0000-0002-3557-0236
Georg E WinterCeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria. gwinter@aithyra.at.ORCID 0000-0001-6606-1437
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted protein degradation is a pharmacological strategy that relies on small molecules such as proteolysis-targeting chimeras (PROTACs) or molecular glues, which induce proximity between a target protein and an E3 ubiquitin ligase to prompt target ubiquitination and proteasomal degradation
Indexed as
Protein Kinase InhibitorsProtein KinasesProteolysisEnzyme StabilityHSP90 Heat-Shock ProteinsHumansLigandsProteasome Endopeptidase Complexsrc-Family KinasesUbiquitinationUbiquitin-Protein LigasesHSP90 Heat-Shock ProteinsLigandsProteasome Endopeptidase ComplexProtein Kinase InhibitorsProtein Kinasessrc-Family KinasesUbiquitin-Protein Ligases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.